US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kairos Pharma, Ltd.

1.09

-0.0800-6.84%

Post-market: 1.01-0.0797-7.31%19:59 EDT

Volume:8.78M

Turnover:9.09M

Market Cap:18.37M

PE:-3.90

High:1.15

Open:1.07

Low:0.9900

Close:1.17

Loading ...

Overview Company News Filings

Maxim Group Remains a Buy on Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Ltd. Announces Participation in H.C. Wainwright 27th Annual Global Investment Conference

Why Is Kairos Pharma Stock (KAPA) Up 170% Today?

Top Midday Gainers

MT Newswires Live

Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views

Promising Potential for Kairos Pharma’s ENV-105: Positive Safety Profile and Efficacy Outlook

Amex Halt Add Info Lst 1.540000

THOMSON REUTERS

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Kairos Pharma Ltd - Env-105 Well Tolerated With Hormone Therapy in Phase 2 Trial

THOMSON REUTERS

Kairos Pharma Announces Positive Safety Results From Phase 2 Trial of Env-105 in Advanced Prostate Cancer

THOMSON REUTERS

Kairos Pharma Ltd - Interim Efficacy Data Expected in September 2025

THOMSON REUTERS

Kairos Pharma Ltd - No Dose-Limiting Toxicities or Unexpected Adverse Events Reported

THOMSON REUTERS

Kapa Gold Inc. Announces Successful 2025 AGM Results

Kairos Pharma Enhances U.S. Investor Relations Strategy

Kairos Pharma Ltd. Conducted Investor Relations Meeting

Promising Developments in Oncology Drive Buy Rating for Kairos Pharma

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Kairos Pharma Presents Promising KROS101 Data at ASCO 2025

Kairos Pharma Unveils Promising Data on Cancer Immunotherapy Drug KROS 101 at ASCO 2025 Annual Meeting

Kairos Pharma Ltd. Announces New Data on Small Molecule Gitr Ligand Agonist Kros 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (Asco) 2025 Annual Meeting

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KAPA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KAPA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","market":"US","secType":"STK","nameCN":"Kairos Pharma, Ltd.","latestPrice":1.09,"timestamp":1752696000000,"preClose":1.17,"halted":0,"volume":8780635,"hourTrading":{"tag":"盘后","latestPrice":1.0103,"preClose":1.09,"latestTime":"19:59 EDT","volume":245941,"amount":252666.761,"timestamp":1752710398053},"delay":0,"floatShares":6222871,"shares":16849306,"eps":-0.279234,"marketStatus":"Not Yet Opened","change":-0.08,"latestTime":"07-16 16:00:00 EDT","open":1.07,"high":1.15,"low":0.99,"amount":9085742.748853002,"amplitude":0.136752,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.279234,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1752739200000},"marketStatusCode":0,"adr":0,"listingDate":1717992000000,"exchange":"NASDAQ","adjPreClose":1.17,"preHourTrading":{"tag":"盘前","latestPrice":1.1,"preClose":1.17,"latestTime":"09:29 EDT","volume":1130029,"amount":1141791.9238725998,"timestamp":1752672599565},"postHourTrading":{"tag":"盘后","latestPrice":1.0103,"preClose":1.09,"latestTime":"19:59 EDT","volume":245941,"amount":252666.761,"timestamp":1752710398053},"volumeRatio":0.179443},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","floatShares":6222871,"roa":"-46.61%","roe":"-149.74%","lyrEps":-0.229208,"volumeRatio":0.179443,"shares":16849306,"dividePrice":0,"high":1.15,"amplitude":0.136752,"preClose":1.17,"low":0.99,"week52Low":0.4,"pbRate":"2.58","week52High":4,"institutionHeld":0,"latestPrice":1.09,"eps":-0.279234,"divideRate":0,"volume":8780635,"delay":0,"ttmEps":-0.279234,"open":1.07,"prevYearClose":1.52,"prevWeekClose":0.71,"prevMonthClose":0.709,"prevQuarterClose":0.709,"fiveDayClose":0.735,"twentyDayClose":0.5405,"sixtyDayClose":0.96},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KAPA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551128096","title":"Maxim Group Remains a Buy on Kairos Pharma, Ltd. (KAPA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2551128096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551128096?lang=en_us&edition=fundamental","pubTime":"2025-07-16 20:35","pubTimestamp":1752669330,"startTime":"0","endTime":"0","summary":"In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on Kairos Pharma, Ltd., with a price target of $4.00. The compa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-remains-a-buy-on-kairos-pharma-ltd-kapa-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-remains-a-buy-on-kairos-pharma-ltd-kapa-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KAIR","KAPA"],"gpt_icon":0},{"id":"2551128462","title":"Kairos Pharma Ltd. Announces Participation in H.C. Wainwright 27th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2551128462","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551128462?lang=en_us&edition=fundamental","pubTime":"2025-07-16 20:30","pubTimestamp":1752669042,"startTime":"0","endTime":"0","summary":"Kairos Pharma Ltd., a clinical-stage biopharmaceutical company specializing in innovative cancer therapeutics, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The company will engage in one-on-one meetings and present at the event, with the presentation available virtually on their website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire  on July 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL31RWvy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2551159821","title":"Why Is Kairos Pharma Stock (KAPA) Up 170% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2551159821","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551159821?lang=en_us&edition=fundamental","pubTime":"2025-07-16 09:26","pubTimestamp":1752629160,"startTime":"0","endTime":"0","summary":"Kairos Pharma stock rallied on Tuesday after it posted positive interim safety results from a clinical trial.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-kairos-pharma-stock-kapa-up-170-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-kairos-pharma-stock-kapa-up-170-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","BK4139","KAIR"],"gpt_icon":0},{"id":"2551199715","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2551199715","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551199715?lang=en_us&edition=fundamental","pubTime":"2025-07-16 01:40","pubTimestamp":1752601247,"startTime":"0","endTime":"0","summary":"Longevity Health  shares almost doubled amid heavy trading after the company said late Monday that it will merge with THPlasma in a deal valued up to $79 million.More than 98 million shares traded intraday compared with a daily average of about 512,000.Kairos Pharma  reported Tuesday positive safety results from an ongoing phase 2 trial of ENV-105 in advanced prostate cancer.Shares surged 54% as intraday trading volume climbed to more than 226.8 million from a daily average of about 900,000.Apple  has signed a $500 million long-term agreement with MP Materials , the latter said Tuesday.Under the terms of the partnership, MP Materials will provide Apple with magnets produced at its Fort Worth, Texas, facility using recycled feedstock processed at its Mountain Pass site in California.Shares of MP advanced 23% as intraday trading volume catapulted to more than 57.5 million from a daily average of about 11.5 million.Price: 5.22, Change: +2.58, Percent Change: +97.35","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0882574139.USD","MP","LU0109391861.USD","LU1366192091.USD","LU2361045086.USD","IE00BJTD4V19.USD","IE00B19Z9505.USD","LU1261432733.SGD","LU1934455863.HKD","LU2168564495.EUR","SG9999002232.USD","LU2430703251.USD","LU0251132253.USD","LU1642822529.SGD","LU2237443978.SGD","LU2065169927.USD","SG9999015952.SGD","LU0784385840.USD","LU2168564149.EUR","IE00B4YYXB79.USD","LU1127390331.HKD","LU1629891620.HKD","LU2168563687.JPY","LU2087621335.USD","IE00B4JS1V06.HKD","LU0719512351.SGD","LU1551013425.SGD","SG9999014542.SGD","LU0820562030.AUD","LU2242650005.HKD","LU1145028129.USD","LU1868836757.USD","BK4170","IE0009356076.USD","XAGE","SG9999015358.SGD","LU0345770308.USD","KAPA","LU0820561909.HKD","LU0784385170.HKD","LU1974910355.USD","LU1496350502.SGD","MACW.SI","LU1582986359.USD","IE00B775SV38.USD","LU2092937148.SGD","LU0861579265.USD","LU2023250330.USD","LU2458330243.SGD"],"gpt_icon":1},{"id":"2551719659","title":"Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views","url":"https://stock-news.laohu8.com/highlight/detail?id=2551719659","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551719659?lang=en_us&edition=fundamental","pubTime":"2025-07-16 00:06","pubTimestamp":1752595564,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/07/46423299/nasdaq-gains-over-100-points-wells-fargo-earnings-top-views","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WFC","SLP","RVYL","XAGE","BLMZ","PCOM",".IXIC","NDAQ","RANI","KAPA"],"gpt_icon":0},{"id":"2551195226","title":"Promising Potential for Kairos Pharma’s ENV-105: Positive Safety Profile and Efficacy Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2551195226","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551195226?lang=en_us&edition=fundamental","pubTime":"2025-07-15 23:35","pubTimestamp":1752593724,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright rei...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-potential-for-kairos-pharmas-env-105-positive-safety-profile-and-efficacy-outlook-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-potential-for-kairos-pharmas-env-105-positive-safety-profile-and-efficacy-outlook-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","KAPA","BK4139"],"gpt_icon":0},{"id":"2551160917","title":"Amex Halt  Add Info Lst 1.540000","url":"https://stock-news.laohu8.com/highlight/detail?id=2551160917","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551160917?lang=en_us&edition=fundamental","pubTime":"2025-07-15 21:33","pubTimestamp":1752586386,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nAQN2KMUH6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2551162946","title":"Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2551162946","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551162946?lang=en_us&edition=fundamental","pubTime":"2025-07-15 20:02","pubTimestamp":1752580937,"startTime":"0","endTime":"0","summary":"Kairos Pharma Ltd., a clinical-stage biopharmaceutical company, has announced positive safety results from its ongoing Phase 2 clinical trial of ENV-105  for patients with metastatic castration-resistant prostate cancer. The interim safety analysis revealed that the CD105 antagonist, when combined with standard hormone therapy apalutamide, was well tolerated by the first ten patients enrolled in the study. No dose-limiting toxicities or unexpected adverse events were reported, and treatment-related side effects were manageable. No Grade 3 or 4 toxicities were observed. The trial, which aims to enroll 100 patients, is currently accruing participants at multiple locations including Cedars-Sinai Medical Center. Interim efficacy data is expected in September 2025. Kairos Pharma is planning to discuss the design of a potential pivotal Phase 3 study with regulatory agencies based on emerging data.Disclaimer: This news brief was created by Public Technologies  using generative artificial inte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nNDL9nJbRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"gpt_icon":1},{"id":"2551414164","title":"Kairos Pharma Ltd - Env-105 Well Tolerated With Hormone Therapy in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2551414164","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551414164?lang=en_us&edition=fundamental","pubTime":"2025-07-15 20:00","pubTimestamp":1752580805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nTUA8YSTVY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2551164968","title":"Kairos Pharma Announces Positive Safety Results From Phase 2 Trial of Env-105 in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2551164968","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551164968?lang=en_us&edition=fundamental","pubTime":"2025-07-15 20:00","pubTimestamp":1752580805,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nTUA8YSTVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2551164499","title":"Kairos Pharma Ltd - Interim Efficacy Data Expected in September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2551164499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551164499?lang=en_us&edition=fundamental","pubTime":"2025-07-15 20:00","pubTimestamp":1752580805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nTUA8YSTVY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2551164438","title":"Kairos Pharma Ltd - No Dose-Limiting Toxicities or Unexpected Adverse Events Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2551164438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551164438?lang=en_us&edition=fundamental","pubTime":"2025-07-15 20:00","pubTimestamp":1752580805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nTUA8YSTVY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2543632565","title":"Kapa Gold Inc. Announces Successful 2025 AGM Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2543632565","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543632565?lang=en_us&edition=fundamental","pubTime":"2025-06-14 03:02","pubTimestamp":1749841338,"startTime":"0","endTime":"0","summary":"KAPA Gold Inc ( ($TSE:KAPA) ) just unveiled an update. Kapa Gold Inc., a Canadian exploration company focused on gold projects in North America, he...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kapa-gold-inc-announces-successful-2025-agm-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kapa-gold-inc-announces-successful-2025-agm-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4195","AGM","KAPA","BK4139","1OZmain","BK4229"],"gpt_icon":0},{"id":"2543528538","title":"Kairos Pharma Enhances U.S. Investor Relations Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2543528538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543528538?lang=en_us&edition=fundamental","pubTime":"2025-06-13 05:43","pubTimestamp":1749764624,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. ( ($KAPA) ) has provided an announcement. On June 10, 2025, Kairos Pharma, Ltd. entered into a one-year services agreement with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-enhances-u-s-investor-relations-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-enhances-u-s-investor-relations-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4023","BK4596","BK4600","KAIR","KAPA","BK4585","BK4139","BK4595","BK4516","STRK"],"gpt_icon":0},{"id":"2543369540","title":"Kairos Pharma Ltd. Conducted Investor Relations Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2543369540","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543369540?lang=en_us&edition=fundamental","pubTime":"2025-06-13 05:06","pubTimestamp":1749762364,"startTime":"0","endTime":"0","summary":"Kairos Pharma Ltd. held a meeting on June 10, 2025. Proposals included the election of directors, which was approved. Another proposal related to ratifying the appointment of the company's independent auditors was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL6fN7Dl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2541093335","title":"Promising Developments in Oncology Drive Buy Rating for Kairos Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2541093335","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541093335?lang=en_us&edition=fundamental","pubTime":"2025-06-05 01:35","pubTimestamp":1749058512,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Kairos Pharma, Ltd. (KAPA – Research Report), with a pri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-oncology-drive-buy-rating-for-kairos-pharma-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-oncology-drive-buy-rating-for-kairos-pharma-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","KAPA"],"gpt_icon":0},{"id":"2540653063","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2540653063","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540653063?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:53","pubTimestamp":1749037980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 04, 2025 07:53 ET (11:53 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAIR","KAPA"],"gpt_icon":0},{"id":"2540774676","title":"Kairos Pharma Presents Promising KROS101 Data at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2540774676","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540774676?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:45","pubTimestamp":1748954751,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. ( ($KAPA) ) has issued an update. Kairos Pharma Ltd. announced the presentation of new data on its investigational small molecu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-presents-promising-kros101-data-at-asco-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-presents-promising-kros101-data-at-asco-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","KAPA","BK4139"],"gpt_icon":0},{"id":"2540054779","title":"Kairos Pharma Unveils Promising Data on Cancer Immunotherapy Drug KROS 101 at ASCO 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540054779","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540054779?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:15","pubTimestamp":1748952918,"startTime":"0","endTime":"0","summary":"Kairos Pharma Ltd. , a clinical stage biopharmaceutical company, has announced new findings regarding its investigational small molecule GITR ligand agonist, KROS101. Presented at the American Society of Clinical Oncology  2025 Annual Meeting in Chicago, the study highlights KROS101's potential as a cancer immunotherapy. The data indicate that KROS101 exhibits strong activity in enhancing the immune system and targeting tumor cells through its dual mechanism of action. The study demonstrated that KROS101 enhances T cell function by promoting proliferation and increasing cytotoxicity, while also reducing T reg-mediated suppression. The findings suggest that KROS101 is superior to the anti-GITR antibody TRX518 in several aspects, including T cell tumor infiltration and cytotoxicity. The company plans to continue studying KROS101 and engage with the medical and scientific communities regarding these findings.Disclaimer: This news brief was created by Public Technologies  using generative ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL2KTbxy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2540797717","title":"Kairos Pharma Ltd. Announces New Data on Small Molecule Gitr Ligand Agonist Kros 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (Asco) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540797717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540797717?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:15","pubTimestamp":1748952900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA7ZV7B4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":61,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KAPA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KAPA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KAPA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1743739200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KAPA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KAPA","date":"2025-07-15","current":-3.259023,"percent":0.834951,"low":-25.607053,"twenty":-8.578362,"median":-6.233573,"eighty":-4.002289,"high":-2.140651,"avg":-6.598346,"sd":3.35831,"marketCap":11543459},"quantilePoints":[{"date":"2024-09-13","current":-25.607053,"twenty":-25.607053,"median":-25.607053,"eighty":-25.607053,"marketCap":51367748},{"date":"2024-09-20","current":-14.59602,"twenty":-25.607053,"median":-16.196461,"eighty":-14.724055,"marketCap":29279616},{"date":"2024-09-27","current":-10.594918,"twenty":-16.644584,"median":-14.59602,"eighty":-12.803526,"marketCap":21253405},{"date":"2024-10-04","current":-8.706398,"twenty":-15.748337,"median":-12.835535,"eighty":-9.858715,"marketCap":17465034},{"date":"2024-10-11","current":-9.410592,"twenty":-14.724055,"median":-10.594918,"eighty":-8.706398,"marketCap":18877647},{"date":"2024-10-18","current":-9.410592,"twenty":-14.59602,"median":-9.890724,"eighty":-9.026486,"marketCap":18877647},{"date":"2024-10-25","current":-9.602645,"twenty":-14.019861,"median":-9.73068,"eighty":-9.026486,"marketCap":19262905},{"date":"2024-10-31","current":-8.64238,"twenty":-13.098007,"median":-9.602645,"eighty":-8.947104,"marketCap":17336614},{"date":"2024-11-08","current":-8.770415,"twenty":-12.81633,"median":-9.464686,"eighty":-8.64238,"marketCap":17593453},{"date":"2024-11-15","current":-13.158824,"twenty":-13.152678,"median":-9.474609,"eighty":-8.64238,"marketCap":26396601},{"date":"2024-11-22","current":-7.030345,"twenty":-12.924264,"median":-9.410592,"eighty":-8.578362,"marketCap":19270177},{"date":"2024-11-29","current":-7.217821,"twenty":-12.829133,"median":-9.282556,"eighty":-8.469532,"marketCap":19784048},{"date":"2024-12-06","current":-6.608525,"twenty":-12.265778,"median":-9.026486,"eighty":-7.967725,"marketCap":18113966},{"date":"2024-12-13","current":-8.061463,"twenty":-11.119862,"median":-8.738406,"eighty":-7.667763,"marketCap":22096470},{"date":"2024-12-20","current":-7.920856,"twenty":-10.268428,"median":-8.706398,"eighty":-7.780249,"marketCap":21711066},{"date":"2024-12-27","current":-7.827118,"twenty":-9.999554,"median":-8.64238,"eighty":-7.780249,"marketCap":21454130},{"date":"2025-01-03","current":-7.170953,"twenty":-9.909929,"median":-8.578362,"eighty":-7.46154,"marketCap":19655581},{"date":"2025-01-10","current":-4.827504,"twenty":-9.858715,"median":-8.578362,"eighty":-7.311559,"marketCap":13232188},{"date":"2025-01-17","current":-8.295808,"twenty":-9.858715,"median":-8.530349,"eighty":-7.261949,"marketCap":22738809},{"date":"2025-01-24","current":-7.311559,"twenty":-9.756287,"median":-8.373067,"eighty":-7.264142,"marketCap":20040984},{"date":"2025-01-31","current":-6.936607,"twenty":-9.73068,"median":-8.108332,"eighty":-7.170953,"marketCap":19013241},{"date":"2025-02-07","current":-6.749132,"twenty":-9.628252,"median":-8.036517,"eighty":-7.161579,"marketCap":18499370},{"date":"2025-02-14","current":-6.796001,"twenty":-9.602645,"median":-7.967725,"eighty":-7.030345,"marketCap":18627838},{"date":"2025-02-21","current":-6.233573,"twenty":-9.526207,"median":-7.967725,"eighty":-7.030345,"marketCap":17086224},{"date":"2025-02-28","current":-5.671145,"twenty":-9.474865,"median":-7.897422,"eighty":-6.869431,"marketCap":15544609},{"date":"2025-03-07","current":-5.198227,"twenty":-9.462702,"median":-7.803684,"eighty":-6.730384,"marketCap":14248340},{"date":"2025-03-14","current":-4.773372,"twenty":-9.428261,"median":-7.780249,"eighty":-6.44917,"marketCap":13083812},{"date":"2025-03-21","current":-4.898329,"twenty":-9.410592,"median":-7.639642,"eighty":-6.289816,"marketCap":13426320},{"date":"2025-03-28","current":-4.848346,"twenty":-9.33377,"median":-7.452166,"eighty":-6.092966,"marketCap":13289317},{"date":"2025-04-04","current":-4.698397,"twenty":-9.282556,"median":-7.358428,"eighty":-5.577408,"marketCap":12878307},{"date":"2025-04-11","current":-4.948312,"twenty":-9.244146,"median":-7.311559,"eighty":-5.297393,"marketCap":13563323},{"date":"2025-04-17","current":-4.775903,"twenty":-9.141718,"median":-7.263319,"eighty":-5.121191,"marketCap":12431676},{"date":"2025-04-25","current":-5.470376,"twenty":-9.018804,"median":-7.217821,"eighty":-5.172643,"marketCap":14239390},{"date":"2025-05-02","current":-5.034285,"twenty":-8.912535,"median":-7.170953,"eighty":-5.172643,"marketCap":13104245},{"date":"2025-05-09","current":-4.841892,"twenty":-8.744808,"median":-7.124084,"eighty":-5.140524,"marketCap":12603446},{"date":"2025-05-16","current":-2.898471,"twenty":-8.706398,"median":-7.030345,"eighty":-5.053706,"marketCap":10266383},{"date":"2025-05-23","current":-2.643971,"twenty":-8.706398,"median":-7.030345,"eighty":-4.968305,"marketCap":9364944},{"date":"2025-05-30","current":-2.626341,"twenty":-8.693594,"median":-6.936607,"eighty":-4.902727,"marketCap":9302501},{"date":"2025-06-06","current":-2.390394,"twenty":-8.64238,"median":-6.865004,"eighty":-4.843183,"marketCap":8466776},{"date":"2025-06-13","current":-2.711492,"twenty":-8.629576,"median":-6.796001,"eighty":-4.780395,"marketCap":9604104},{"date":"2025-06-20","current":-2.911286,"twenty":-8.578362,"median":-6.702263,"eighty":-4.758377,"marketCap":10311775},{"date":"2025-06-27","current":-3.282332,"twenty":-8.578362,"median":-6.467918,"eighty":-4.698397,"marketCap":11626021},{"date":"2025-07-03","current":-3.096809,"twenty":-8.578362,"median":-6.421049,"eighty":-4.598431,"marketCap":10968898},{"date":"2025-07-11","current":-3.382229,"twenty":-8.578362,"median":-6.327311,"eighty":-4.315248,"marketCap":11979856},{"date":"2025-07-15","current":-3.259023,"twenty":-8.578362,"median":-6.233573,"eighty":-4.002289,"marketCap":11543459}],"updateTime":1752736349415}}}